Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

120.76 +7.63 (+6.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
65 66 Next >
Vaccine Makers Mull Price Increase For COVID-19 Boosters Amid Falling Demand
Via Benzinga
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
Why Moderna Stock Dropped Today
Competition is intensifying. 
Via The Motley Fool
Why Novavax Stock Couldn't Win on Wednesday
FDA authorization isn't necessarily a slam dunk for a company. 
Via The Motley Fool
European Advisory Committee Backs Pfizer/BioNTech's COVID Shot For Younger Kids
Via Benzinga
Pfizer's Partner BioNTech Signs Research Pact With Australia
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
From BioNTech SE
Via GlobeNewswire
Why BioNTech SE And Novavax Shares Are Diving
BioNTech SE - ADR (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 4.07% to $133.28 and 7.68% to $18.76, respectively, ahead of the close of Tuesday's session. Vaccine stock 
Via Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
All three of these medical stocks offer a high-yield dividend. 
Via The Motley Fool
Bulls And Bears Of The Week: Amazon, Tesla, Apple, Meta And Why An Analyst Is Turning Less Positive On 2 Legacy Automakers
Benzinga examined the prospects for many investors' favorite stocks over the past week — here's a look at some of our top stories. 
Via Benzinga
Why Novavax Stock Had an Ugly Friday
Investors ding the biotech's shares one day after it reported quite good news about an experimental vaccine. 
Via The Motley Fool
Pfizer/BioNTech's Updated Omicron Adapted COVID-19 Shot Increases Neutralizing Antibodies Above Pre-Booster Levels
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ:  
Via Benzinga
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
From BioNTech SE
Via GlobeNewswire
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
From Pfizer Inc.
Via Business Wire
These 2 Stocks Gave Investors a Nice Surprise Wednesday
Markets moved slightly lower in advance of the latest data on inflation. 
Via The Motley Fool
Why Pfizer Partner BioNTech SE Shares Are Trading Higher
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 5.37% to $136.45 going into the close of Wednesday's trading session after the FDA granted Emergency Use Authorization to the company's... 
Via Benzinga
FDA Authorizes Pfizer/BioNtech's Updated COVID-19 Booster Shots For Kids 5-11 Years
Via Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
From BioNTech SE
Via GlobeNewswire
Moderna, BioNTech And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
Exposures COVID-19
Dear NVAX Stock Fans, Mark Your Calendars for Oct. 11
Shares of NVAX stock are climbing ahead of the World Vaccine Congress Europe 2022, where Novavax will share new vaccine data. 
Via InvestorPlace
Pfizer's Executive Says European COVID-19 Vaccine Contract Negotiations Did Not Happen Over Text Message
A Pfizer Inc (NYSE: PFE) executive has "categorically" ruled out that the pharma giant's chief executive agreed on the European COVID-19 contract via mobile phone text messages. 
Via Benzinga
7 Blue-Chip Stocks That Are Too Cheap to Ignore
It's time to pounce on the opportunity to buy high-quality at bargain prices, with these seven cheap blue-chip stocks. 
Via InvestorPlace
3 Dirt-Cheap Stocks That Could Soar 48% to 68%, According to Wall Street
These stocks could attract both value and growth investors. 
Via The Motley Fool
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
From BioNTech SE
Via GlobeNewswire
Top Five Weekend Stock Stories - Sunday, Oct. 2nd
Catch up on the weekend's top five stories with this must read list. 
Via Talk Markets
As Moderna Grapples With Supply Shortage, FDA Gives Nod To Additional Lots of COVID-19 Booster
Via Benzinga
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over. 
Via InvestorPlace
iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26
Bloomberg 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.